Characterization of Serotonin Signaling Components in Patients with Inflammatory Bowel Disease

Overview

Journal J Can Assoc Gastroenterol

Publisher Oxford University Press

Specialty Gastroenterology

Date 2019 Jul 12

PMID 31294376

Citations 25

Authors

Md Sharif Shajib

Usha Chauhan

Salman Adeeb

Yeshale Chetty

David Armstrong

Smita L S Halder

John K Marshall

Waliul I Khan

Affiliations

Soon will be listed here.

Abstract

Background: Tryptophan hydroxylase (TPH)1 catalyzes the biosynthesis of serotonin (5-hydroxytrptamine; 5-HT) in enterochromaffin (EC) cells, the predominant source of gut 5-HT. Secreted 5-HT regulates various gut functions through diverse 5-HT receptor (5-HTR) families, and 5-HT transporter (5-HTT) sequesters its activity via uptake into surrounding cells. In inflammatory bowel disease (IBD) mucosal 5-HT signaling is altered, including upregulated EC cell numbers and 5-HT levels. We examined key mucosal 5-HT signaling components and blood 5-HT levels and, as part of a pilot study, investigated the association between 5-HTT gene-linked polymorphic region (5HTTLPR) and Crohn's disease (CD).

Methods: In the context of inflammation, colonic expressions of TPH1, 5-HTT and 5-HTRs were studied in CD patients (n=15) and healthy controls (HC; n=10) using quantitative polymerase chain reaction (qPCR). We also investigated 5HTTLPR in 40 CD patients and HC utilizing PCR and measured platelet-poor plasma (PPP) and plasma 5-HT concentrations.

Results: Compared with HC, inflammation in CD patients was associated with elevated TPH1, 5-HTR3, 5-HTR4, 5-HTR7 and downregulated 5-HTT expressions. In our second cohort of participants, significantly higher PPP and plasma 5-HT levels and higher S-genotype (L/S+S/S) than L/L genotype were observed in CD patients compared with HC.

Conclusion: Our results suggest that augmented mucosal 5-HT signaling and specific 5-HTTLPR genotype-associated decreased efficiency in 5-HT reuptake, the latter through increased 5-HT availability, may contribute to inflammation in CD patients. These findings revealed important information on various components of 5-HT signaling in intestinal inflammation which may ultimately lead to effective strategies targeting this pathway in IBD.

Citing Articles

Mesenchymal GDNF promotes intestinal enterochromaffin cell differentiation.

Lemmetyinen T, Viitala E, Wartiovaara L, Paivinen P, Virtanen H, Pentinmikko N iScience. 2024; 27(12):111246.

PMID: 39634560 PMC: 11616604. DOI: 10.1016/j.isci.2024.111246.

Alterations in tryptophan metabolism and NAD biosynthesis within the microbiota-gut-brain axis in chronic intestinal inflammation.

Devereaux J, Robinson A, Stavely R, Davidson M, Dargahi N, Ephraim R Front Med (Lausanne). 2024; 11:1379335.

PMID: 39015786 PMC: 11250461. DOI: 10.3389/fmed.2024.1379335.

Novel 5-HT receptor antagonists modulate intestinal immune responses and reduce severity of colitis.

Kwon Y, Blass B, Wang H, Grondin J, Banskota S, Korzekwa K Am J Physiol Gastrointest Liver Physiol. 2024; 327(1):G57-G69.

PMID: 38713616 PMC: 11550998. DOI: 10.1152/ajpgi.00299.2023.

Emerging Roles of Gut Serotonin in Regulation of Immune Response, Microbiota Composition and Intestinal Inflammation.

Grondin J, Khan W J Can Assoc Gastroenterol. 2024; 7(1):88-96.

PMID: 38314177 PMC: 10836984. DOI: 10.1093/jcag/gwad020.

Serotonin Metabolism and Serotonin Receptors Expression Are Altered in Colon Diverticulosis.

Jastrzebski M, Nehring P, Joniec-Maciejak I, Wawer A, Przybylkowski A Medicina (Kaunas). 2023; 59(11).

PMID: 38003994 PMC: 10673248. DOI: 10.3390/medicina59111945.

References

Magro F, Vieira-Coelho M, Fraga S, Serrao M, Veloso F, Ribeiro T . Impaired synthesis or cellular storage of norepinephrine, dopamine, and 5-hydroxytryptamine in human inflammatory bowel disease. Dig Dis Sci. 2002; 47(1):216-24. DOI: 10.1023/a:1013256629600. View

Willeit M, Praschak-Rieder N, Neumeister A, Zill P, Leisch F, Stastny J . A polymorphism (5-HTTLPR) in the serotonin transporter promoter gene is associated with DSM-IV depression subtypes in seasonal affective disorder. Mol Psychiatry. 2003; 8(11):942-6. DOI: 10.1038/sj.mp.4001392. View

Loftus Jr E . Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology. 2004; 126(6):1504-17. DOI: 10.1053/j.gastro.2004.01.063. View

Coates M, Mahoney C, Linden D, Sampson J, Chen J, Blaszyk H . Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology. 2004; 126(7):1657-64. DOI: 10.1053/j.gastro.2004.03.013. View

Chamouard P, Richert Z, Meyer N, Rahmi G, Baumann R . Diagnostic value of C-reactive protein for predicting activity level of Crohn's disease. Clin Gastroenterol Hepatol. 2006; 4(7):882-7. DOI: 10.1016/j.cgh.2006.02.003. View

Bernstein C, Wajda A, Svenson L, MacKenzie A, Koehoorn M, Jackson M . The epidemiology of inflammatory bowel disease in Canada: a population-based study. Am J Gastroenterol. 2006; 101(7):1559-68. DOI: 10.1111/j.1572-0241.2006.00603.x. View

Danese S, Papa A, Saibeni S, Repici A, Malesci A, Vecchi M . Inflammation and coagulation in inflammatory bowel disease: The clot thickens. Am J Gastroenterol. 2006; 102(1):174-86. DOI: 10.1111/j.1572-0241.2006.00943.x. View

Mousavizadeh K, Rahimian R, Fakhfouri G, Aslani F, Ghafourifar P . Anti-inflammatory effects of 5-HT receptor antagonist, tropisetron on experimental colitis in rats. Eur J Clin Invest. 2009; 39(5):375-83. DOI: 10.1111/j.1365-2362.2009.02102.x. View

Ghia J, Li N, Wang H, Collins M, Deng Y, El-Sharkawy R . Serotonin has a key role in pathogenesis of experimental colitis. Gastroenterology. 2009; 137(5):1649-60. DOI: 10.1053/j.gastro.2009.08.041. View

10.

Docherty M . Elevated serotonin associated with collagenous colitis. Am J Gastroenterol. 2010; 105(6):1449. DOI: 10.1038/ajg.2010.90. View

11.

Fedorak R, Wong K, Bridges R . Canadian Digestive Health Foundation Public Impact Series. Inflammatory bowel disease in Canada: Incidence, prevalence, and direct and indirect economic impact. Can J Gastroenterol. 2010; 24(11):651-5. PMC: 3004417. DOI: 10.1155/2010/407095. View

12.

Jurgens M, Mahachie John J, Cleynen I, Schnitzler F, Fidder H, van Moerkercke W . Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2011; 9(5):421-7.e1. DOI: 10.1016/j.cgh.2011.02.008. View

13.

Matricon J, Barnich N, Ardid D . Immunopathogenesis of inflammatory bowel disease. Self Nonself. 2011; 1(4):299-309. PMC: 3062384. DOI: 10.4161/self.1.4.13560. View

14.

Qin X . What made Canada become a country with the highest incidence of inflammatory bowel disease: could sucralose be the culprit?. Can J Gastroenterol. 2011; 25(9):511. PMC: 3202359. DOI: 10.1155/2011/451036. View

15.

Manocha M, Shajib M, Rahman M, Wang H, Rengasamy P, Bogunovic M . IL-13-mediated immunological control of enterochromaffin cell hyperplasia and serotonin production in the gut. Mucosal Immunol. 2012; 6(1):146-55. DOI: 10.1038/mi.2012.58. View

16.

Gershon M . 5-Hydroxytryptamine (serotonin) in the gastrointestinal tract. Curr Opin Endocrinol Diabetes Obes. 2012; 20(1):14-21. PMC: 3708472. DOI: 10.1097/MED.0b013e32835bc703. View

17.

Kenna G, Roder-Hanna N, Leggio L, Zywiak W, Clifford J, Edwards S . Association of the 5-HTT gene-linked promoter region (5-HTTLPR) polymorphism with psychiatric disorders: review of psychopathology and pharmacotherapy. Pharmgenomics Pers Med. 2012; 5:19-35. PMC: 3513226. DOI: 10.2147/PGPM.S23462. View

18.

Manocha M, Khan W . Serotonin and GI Disorders: An Update on Clinical and Experimental Studies. Clin Transl Gastroenterol. 2012; 3:e13. PMC: 3365677. DOI: 10.1038/ctg.2012.8. View

19.

Kim J, Bridle B, Ghia J, Wang H, Syed S, Manocha M . Targeted inhibition of serotonin type 7 (5-HT7) receptor function modulates immune responses and reduces the severity of intestinal inflammation. J Immunol. 2013; 190(9):4795-804. DOI: 10.4049/jimmunol.1201887. View

20.

Jovani M, Fiorino G, Danese S . Anti-IL-13 in inflammatory bowel disease: from the bench to the bedside. Curr Drug Targets. 2013; 14(12):1444-52. DOI: 10.2174/13894501113149990170. View